2025
Evaluating Major Bleeding Risks with Concomitant Use of Direct Oral Anticoagulants and Selective Serotonin Reuptake Inhibitors in Nonvalvular Atrial Fibrillation Patients
Yao S, Kocis P, Murphy T, Hwang W. Evaluating Major Bleeding Risks with Concomitant Use of Direct Oral Anticoagulants and Selective Serotonin Reuptake Inhibitors in Nonvalvular Atrial Fibrillation Patients. Pharmacoepidemiology 2025, 4: 6. DOI: 10.3390/pharma4010006.Peer-Reviewed Original ResearchDirect oral anticoagulantsNonvalvular atrial fibrillationNonvalvular atrial fibrillation patientsVitamin K antagonistsSerotonin reuptake inhibitorsHazard ratioBleeding eventsConcomitant useOral anticoagulantsReuptake inhibitorsFollow-upConfidence intervalsElectronic health recordsEstimate hazard ratiosCause-specific proportional hazards modelDOAC prescriptionsHAS-BLED scoreAtrial fibrillation patientsBaseline CHA2DS2-VASc scoreCHA2DS2-VASc scoreRetrospective cohort studyInverse probability of treatmentHealth recordsProportional hazards modelDrug-drug interactionsState of the Art in Left Atrial Appendage Occlusion
Garg J, Kabra R, Gopinathannair R, Di Biase L, Wang D, Saw J, Hahn R, Freeman J, Ellis C, Lakkireddy D. State of the Art in Left Atrial Appendage Occlusion. JACC Clinical Electrophysiology 2025, 11: 602-641. PMID: 39797854, DOI: 10.1016/j.jacep.2024.10.024.Peer-Reviewed Original ResearchConceptsLeft atrial appendage occlusionAppendage occlusionStroke preventionLeft atrial appendage occlusion devicesNonvalvular atrial fibrillationOptimal patient selectionDevice-related thrombusLeft atrial appendagePericardial effusionPostprocedural complicationsPatient selectionAtrial fibrillationAtrial appendageArrhythmia therapyDevice leakTherapeutic targetClinical needOcclusionPreventionStroke
2023
Identifying treatment heterogeneity in atrial fibrillation using a novel causal machine learning method
Ngufor C, Yao X, Inselman J, Ross J, Dhruva S, Graham D, Lee J, Siontis K, Desai N, Polley E, Shah N, Noseworthy P, MN; New Haven C. Identifying treatment heterogeneity in atrial fibrillation using a novel causal machine learning method. American Heart Journal 2023, 260: 124-140. PMID: 36893934, PMCID: PMC10615250, DOI: 10.1016/j.ahj.2023.02.015.Peer-Reviewed Original ResearchConceptsOral anticoagulantsAtrial fibrillationPatient subgroupsComposite outcomeIschemic strokeEffect of OACsLifelong oral anticoagulationNonvitamin K antagonistNew oral anticoagulantsNonvalvular atrial fibrillationPrimary composite outcomeGlomerular filtration rateFuture prospective studiesOptumLabs Data WarehousePopulation-level effectivenessOAC useOral anticoagulationVASc scoreCause mortalityK antagonistsPrimary endpointWarfarin usersRenal functionAF patientsEntire cohort
2022
Device-Sizing and Associated Complications With Left Atrial Appendage Occlusion: Findings From the NCDR LAAO Registry
Sandhu A, Varosy P, Du C, Aleong R, Tumolo A, West J, Tzou W, Curtis J, Freeman J, Friedman D, Hess P. Device-Sizing and Associated Complications With Left Atrial Appendage Occlusion: Findings From the NCDR LAAO Registry. Circulation Cardiovascular Interventions 2022, 15: e012183. PMID: 36472194, DOI: 10.1161/circinterventions.122.012183.Peer-Reviewed Original ResearchConceptsAtrial appendage occlusionAppendage occlusionPericardial effusionLower oddsOversized deviceComposite adverse outcomeNonvalvular atrial fibrillationShort-term complicationsShort-term outcomesSignificant leakDevice embolismSelect patientsAdverse eventsWatchman deviceAssociated complicationsPeridevice leakAtrial fibrillationAdverse outcomesDevice embolizationHigh prevalenceDevice migrationManufacturer's recommendationsPatientsStudy periodUndersized devicesLeft Atrial Appendage Occlusion Versus Oral Anticoagulation in Atrial Fibrillation : A Decision Analysis.
Chew DS, Zhou K, Pokorney SD, Matchar DB, Vemulapalli S, Allen LA, Jackson KP, Samad Z, Patel MR, Freeman JV, Piccini JP. Left Atrial Appendage Occlusion Versus Oral Anticoagulation in Atrial Fibrillation : A Decision Analysis. Annals Of Internal Medicine 2022, 175: 1230-1239. PMID: 35969865, DOI: 10.7326/m21-4653.Peer-Reviewed Original ResearchConceptsDirect oral anticoagulantsHigh bleeding riskLower stroke riskClinical effectiveness dataAtrial fibrillationBleeding riskStroke riskOral anticoagulantsIschemic strokeEffectiveness dataHAS-BLED scoreIndividual riskHigh stroke riskMajor bleeding riskNonvalvular atrial fibrillationPatient's individual riskPrimary end pointAtrial appendage occlusionBase-case analysisOral anticoagulationPrior strokeVASc scoreStroke preventionWatchman deviceAppendage occlusion
2020
Risk Factors Associated With Ischemic Stroke in Japanese Patients With Nonvalvular Atrial Fibrillation
Okumura K, Tomita H, Nakai M, Kodani E, Akao M, Suzuki S, Hayashi K, Sawano M, Goya M, Yamashita T, Fukuda K, Ogawa H, Tsuda T, Isobe M, Toyoda K, Miyamoto Y, Miyata H, Okamura T, Sasahara Y. Risk Factors Associated With Ischemic Stroke in Japanese Patients With Nonvalvular Atrial Fibrillation. JAMA Network Open 2020, 3: e202881. PMID: 32293685, PMCID: PMC7160687, DOI: 10.1001/jamanetworkopen.2020.2881.Peer-Reviewed Original ResearchConceptsNonvalvular atrial fibrillationFushimi AF RegistryJ-RHYTHM RegistryRisk stratification schemesIschemic strokeAF RegistryBody mass indexRisk factorsAtrial fibrillationJapanese patientsPermanent AFPrevious strokeMass indexShinken DatabaseStratification schemesCox proportional hazards analysisLower body mass indexOral anticoagulant useIndependent risk factorProportional hazards analysisSignificant risk factorsIndividual patient dataValvular AFAnticoagulant useCohort study
2018
Cardioembolic Stroke Risk and Recovery After Anticoagulation-Related Intracerebral Hemorrhage
Murphy MP, Kuramatsu JB, Leasure A, Falcone GJ, Kamel H, Sansing LH, Kourkoulis C, Schwab K, Elm JJ, Gurol ME, Tran H, Greenberg SM, Viswanathan A, Anderson CD, Schwab S, Rosand J, Shi FD, Kittner SJ, Testai FD, Woo D, Langefeld CD, James ML, Koch S, Huttner HB, Biffi A, Sheth KN. Cardioembolic Stroke Risk and Recovery After Anticoagulation-Related Intracerebral Hemorrhage. Stroke 2018, 49: 2652-2658. PMID: 30355194, PMCID: PMC6211810, DOI: 10.1161/strokeaha.118.021799.Peer-Reviewed Original ResearchConceptsCardioembolic stroke riskOral anticoagulation therapyRankin Scale scoreIntracerebral hemorrhageFunctional recoveryStroke riskAnticoagulation resumptionVASc scoreRecurrent strokeAnticoagulation therapyScale scoreAnticoagulation-related intracerebral hemorrhageDecreased likelihoodSurvivors of ICHModified Rankin Scale scoreNonvalvular atrial fibrillationRecurrent intracerebral hemorrhageOral anticoagulation treatmentICH survivorsTherapy resumptionAnticoagulation treatmentCardioembolic strokeIschemic strokeAtrial fibrillationIndex event
2015
Genetic mutations in African patients with atrial fibrillation: Rationale and design of the Study of Genetics of Atrial Fibrillation in an African Population (SIGNAL)
Bloomfield GS, Temu TM, Akwanalo CO, Chen PS, Emonyi W, Heckbert SR, Koech MM, Manji I, Shen C, Vatta M, Velazquez EJ, Wessel J, Kimaiyo S, Inui TS. Genetic mutations in African patients with atrial fibrillation: Rationale and design of the Study of Genetics of Atrial Fibrillation in an African Population (SIGNAL). American Heart Journal 2015, 170: 455-464.e5. PMID: 26385028, PMCID: PMC4575772, DOI: 10.1016/j.ahj.2015.06.008.Peer-Reviewed Original ResearchConceptsValvular atrial fibrillationNonvalvular atrial fibrillationValvular heart diseaseAtrial fibrillationHeart diseaseCurrent tobacco smokingHistory of strokeCase-control studyGroup morbidityGenetic associationTobacco smokingSaharan AfricaMean ageAfrican patientsCardiovascular diseaseClinical phenotypingFibrillationPrimary analysisPatientsControl populationGenetic testingMorbidityDiseaseGenetic mutationsMost participants
2012
Quality of anticoagulation with warfarin in patients with nonvalvular atrial fibrillation in the community setting
Han SY, Palmeri ST, Broderick SH, Hasselblad V, Rendall D, Stevens S, Tenaglia A, Velazquez E, Whellan D, Wagner G, Heitner JF. Quality of anticoagulation with warfarin in patients with nonvalvular atrial fibrillation in the community setting. Journal Of Electrocardiology 2012, 46: 45-50. PMID: 23063241, DOI: 10.1016/j.jelectrocard.2012.08.011.Peer-Reviewed Original ResearchConceptsNonvalvular atrial fibrillationQuality of anticoagulationAtrial fibrillationTherapeutic rangeStroke preventionPrimary careCardiology practiceRecent large randomized control trialsNew oral anticoagulation agentsPrimary care practice patientsCardiovascular disease risk factorsOne-year periodTreatment of AFInternational normalized ratio (INR) valuesLarge randomized control trialsOral anticoagulation agentsMean therapeutic rangeOral anticoagulation therapyDisease risk factorsPrimary care practicesNovel pharmacologic agentsMulti-center studyCurrent clinical practiceRandomized control trialPrimary care groupsA Pilot Randomized Controlled Trial of a Decision Support Tool to Improve the Quality of Communication and Decision‐Making in Individuals with Atrial Fibrillation
Fraenkel L, Street RL, Towle V, O'Leary JR, Iannone L, Van Ness P, Fried TR. A Pilot Randomized Controlled Trial of a Decision Support Tool to Improve the Quality of Communication and Decision‐Making in Individuals with Atrial Fibrillation. Journal Of The American Geriatrics Society 2012, 60: 1434-1441. PMID: 22861171, PMCID: PMC3419306, DOI: 10.1111/j.1532-5415.2012.04080.x.Peer-Reviewed Original ResearchConceptsNonvalvular atrial fibrillationIntervention participantsAtrial fibrillationControl groupTreatment planPrimary care clinicsCurrent treatment planPatient-clinician communicationPhysician-patient communicationDecisional Conflict ScaleSecondary outcomesPrimary outcomeStroke riskCare clinicsControlled TrialsIntervention groupSide effectsValues clarityMedicationsFibrillationStrokeLower scoresRiskTrialsVisits
2010
Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, Wang PJ, Turakhia MP. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Annals Of Internal Medicine 2010, 154: 1-11. PMID: 21041570, DOI: 10.7326/0003-4819-154-1-201101040-00289.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAnticoagulantsAtrial FibrillationBenzimidazolesbeta-AlanineCost-Benefit AnalysisDabigatranFibrinolytic AgentsHemorrhageHumansIntracranial HemorrhagesIschemic Attack, TransientMarkov ChainsMyocardial InfarctionQuality-Adjusted Life YearsRisk FactorsSensitivity and SpecificityStrokeWarfarinConceptsHigh-dose dabigatranIncremental cost-effectiveness ratioNonvalvular atrial fibrillationLow-dose dabigatranCost-effectiveness ratioAtrial fibrillationIschemic strokeCost of dabigatranIntracranial hemorrhageClinical trialsOral direct thrombin inhibitorVeterans Affairs Health Services ResearchSingle randomized clinical trialAdjusted-dose warfarinStudies of anticoagulationPatients 65 yearsRE-LY trialDirect thrombin inhibitorRandomized clinical trialsAmerican Heart AssociationQuality-adjusted life expectancyQuality-adjusted survivalBase-case analysisHealth services researchStroke prevention
2008
ACC/AHA/Physician Consortium 2008 Clinical Performance Measures for Adults With Nonvalvular Atrial Fibrillation or Atrial Flutter A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and the Physician Consortium for Performance Improvement (Writing Committee to Develop Clinical Performance Measures for Atrial Fibrillation) Developed in Collaboration With the Heart Rhythm Society
Estes NA, Halperin JL, Calkins H, Ezekowitz MD, Gitman P, Go AS, McNamara RL, Messer JV, Ritchie JL, Romeo SJ, Waldo AL, Wyse DG, Bonow RO, DeLong E, Goff DC, Grady K, Green LA, Hiniker A, Linderbaum JA, Masoudi FA, Piña IL, Pressler S, Radford MJ, Rumsfeld JS. ACC/AHA/Physician Consortium 2008 Clinical Performance Measures for Adults With Nonvalvular Atrial Fibrillation or Atrial Flutter A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and the Physician Consortium for Performance Improvement (Writing Committee to Develop Clinical Performance Measures for Atrial Fibrillation) Developed in Collaboration With the Heart Rhythm Society. Journal Of The American College Of Cardiology 2008, 51: 865-884. PMID: 18294574, DOI: 10.1016/j.jacc.2008.01.006.Peer-Reviewed Original Research
2003
Anticoagulation in the Elderly
Dhond AJ, Michelena HI, Ezekowitz MD. Anticoagulation in the Elderly. The American Journal Of Geriatric Cardiology 2003, 12: 243-250. PMID: 12888705, DOI: 10.1111/j.1076-7460.2003.02010.x.Peer-Reviewed Original ResearchFactors influencing physicians' reported use of anticoagulation therapy in nonvalvular atrial fibrillation: A cross-sectional survey
Gross CP, Vogel EW, Dhond AJ, Marple CB, Edwards RA, Hauch O, Demers EA, Ezekowitz M. Factors influencing physicians' reported use of anticoagulation therapy in nonvalvular atrial fibrillation: A cross-sectional survey. Clinical Therapeutics 2003, 25: 1750-1764. PMID: 12860496, DOI: 10.1016/s0149-2918(03)80167-4.Peer-Reviewed Original ResearchConceptsNonvalvular atrial fibrillationCerebrovascular accidentAtrial fibrillationPhysicians' attitudesBenefits of warfarinMajor bleeding episodesUse of warfarinEmbolic cerebrovascular accidentAmerican Medical Association MasterfileMultivariate logistic regressionCross-sectional studyHigher risk estimatesCross-sectional surveyCase vignettesWarfarin useAnticoagulation therapyBleeding episodesElderly patientsWarfarin therapyComorbid conditionsIntracerebral hemorrhageRisk factorsTreatment recommendationsPhysician ageMedian number
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply